Recent Updates
Recently added Catalysts
IVVD Positive Sentiment Score: 70/100

Invivyd to Participate in Upcoming Investor Conferences

Thursday, September 5, 2024 2 min read
Key Takeaway: Invivyd, Inc. announced its participation in several upcoming investor conferences, including the Morgan Stanley Global Healthcare Conference and the H.C. Wainwright Investment Conference. The company is focused on protecting against serious viral infectious diseases, utilizing its proprietary INVYMAB platform. This technology allows for the rapid generation of monoclonal antibodies to combat evolving viral threats. Invivyd recently received emergency use authorization from the FDA for its first monoclonal antibody treatment, showcasing its innovation in the biopharmaceutical sector.

Market Sentiment Analysis

POSITIVE FACTORS

  • Invivyd will participate in multiple investor conferences, indicating active engagement with the investment community.
  • The company's innovative INVYMAB platform shows promise in addressing evolving viral threats.
  • The recent emergency use authorization from the U.S. FDA highlights the company's regulatory success.

Full Press Release Details

WALTHAM, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that it will present at the following investor conferences:
Morgan Stanley 22nd Annual Global Healthcare Conference
Fireside Chat Date: Friday, September 6, 2024
Fireside Chat Time: 10:00 AM ET
Location: New York, NY
H.C. Wainwright 26th Annual Global Investment Conference
Fireside Chat Date: Monday, September 9, 2024
Fireside Chat Time: 9:30 AM ET
Location: New York, NY
2024 Cantor Global Healthcare Conference
Fireside Chat Date: Wednesday, September 18, 2024
Fireside Chat Time: 10:55 AM ET
Location: New York, NY
Live webcasts of the fireside chats will be available in the investor section of the company’s website at investors.invivyd.com and will be archived for approximately 90 days following the events.
Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. The company’s proprietary INVYMAB™ platform approach combines state-of-the-art viral surveillance and predictive modeling with advanced antibody engineering. INVYMAB is designed to facilitate the rapid, serial generation of new monoclonal antibodies (mAbs) to address evolving viral threats. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for its first mAb in a planned series of innovative antibody candidates. Visit https://invivyd.com/ to learn more.
investors@invivyd.com

Frequently Asked Questions

When is Invivyd's fireside chat at the Morgan Stanley conference?

The fireside chat is on September 6, 2024, at 10:00 AM ET.

Where will the H.C. Wainwright conference take place?

The H.C. Wainwright conference will be held in New York, NY.

What is the focus of Invivyd, Inc.?

Invivyd focuses on protecting against serious viral infectious diseases.

How can I watch the live webcasts of the conferences?

Live webcasts will be available on Invivyd's investor website.

What authorization did Invivyd receive in March 2024?

Invivyd received emergency use authorization for its first monoclonal antibody.

Tags: IVVD Viatris Investor Conferences Healthcare Invivyd monoclonal antibodies SARS-CoV-2 U.S. FDA
Last updated: Sep 5, 2024